CHLA Clinical Research Studies

Having volunteers participate in research studies and clinical trials is critical to our research efforts. Thousands of children and families are involved in our patient-centered studies every year. Many of the treatments used today are based on the results of past research studies and clinical trials conducted with our patients. Our scientific and clinical experts take the best ideas from the laboratory -- to the patient -- in the form of promising new treatments.

By searching our study directory, you may identify research that could impact the life of your child or of another child you know. Because the number of available research studies and clinical trials for children nationwide is small, every participant makes a significant contribution.

In addition to enrolling children with certain diseases in order to study treatments and prevention of those diseases, we also need to study healthy children. Ask your child’s doctor about volunteer study options that may be suitable for your child.

Please contact the study staff listed in your search results for more information.

Search by Keyword:    

Back to the full listing

Study Details - ID: CHLA-19-00127
Health/Science/Disease Category:
Glucocorticoid-Induced Osteoporosis (GIOP)
Short Name:
Denosumab treatment for glucocorticoid-induced osteoporosis.
Full Title of Study:
A phase 3 randomized, double-blind, placebo-controlled, Parallel-group Study to evaluate the safety and efficacy of Denosumab / Prolia in Pediatric Subjects with Glucocorticoid-Induced Osteoporosis
Phase/Type of Study:
Phase 3 / drug treatment
Purpose of Research:
This study will evaluate the effect of denosumab on lumbar spine mineral density (BMD), as assessed by dual-energy X-Ray absorpitometry (DEXA) at 12 months in children 5 to 17 years of age with GIOP.
Eligibility:
5 years to 17 years with Glucocorticoid-Induced Osteoporosis
Time Commitment/Requirements:
3 years with 11 visits. Compensation provided.
Primary Investigator:
Anna Ryabets-Lienhard, DO
Coordinator Contact Name:
Dalia Salazar
Phone Number:
323-361-1920
Email:
dasalazar@chla.usc.edu
Clinical Trials .Gov Identifier:
NCT03164928